Replies to post #233 on Equity Field Notes from temporal sources

[DanWebzster]

AQXP failed Ph3 Cystitis Pain Syndrome trial.

With ~$92.7mn in the bank this company is a reverse merger candidate

Otherwise, the next milestone is 7/19 POC study in patients with chronic prostatitis/pelvic pain syndrome.

Best scenario might be cancelling this study and actively pursuing a reverse merger.